In Vivo CAR-T Revolution Series– category –
-
Where Is CAR-T Heading? 3 Commercialization Paths (Autologous/Allogeneic/In Vivo) and the Next-Decade Optimal Mix | Vol.3 (Final)
Structural comparison of CAR-T's three commercialization paths (autologous, allogeneic, in vivo) across 7 axes. Market projection: $16.5B in 2030, $35B in 2035, with in vivo's late-decade growth. Final volume. -
How Is In Vivo CAR-T’s Competitive Structure Shifting? AbbVie-Capstan, Lilly-(Orna+Kelonia), and the 3 Independents Mapping the Two-Camp Era | Vol.2
Comparing 5 in vivo CAR-T companies (Capstan, Umoja, Orna, Renagade, Sana) on technology platform (LNP-mRNA, LV, circular RNA, multi-organ LNP), indication focus (autoimmune vs cancer), strategic partners (Pfizer, Lilly, Merck). Vol. 2. -
Where Is In Vivo CAR-T Heading? How Lilly’s Two-Step (Orna + Kelonia) Redefines Gene Therapy’s Core | In Vivo CAR-T Revolution Vol.1
April 21, 2026 Eli Lilly to acquire Kelonia Therapeutics for up to $7B—the largest in vivo CAR-T M&A signaling pharma majors' serious entry. Kelonia's PreciseTarget LNP delivers CAR mRNA to T cells in vivo, softening ex vivo CAR-T's three walls (manufacturing time, cost, toxicity) simultaneously. Vol. 1.
1